Sarepta Therapeutics SRPT
NASDAQ SRPT
$18.70 -0.47 (-2.45%)
As of: Oct 21, 2026 · 11:41 AM EDT

Sarepta Therapeutics (SRPT) Construction in Progress (2013)

Updated

Sarepta Therapeutics (SRPT) recorded Construction in Progress of $11.3 million in Q4 2013.

Analysis

Sarepta Therapeutics (SRPT) Construction in Progress (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn -
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn -
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn -
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn -
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn -
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn -
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn -
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn -
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn -
10 Sarepta Therapeutics 1.97 Bn -1.26 Bn 251.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 11.30 Mn
API Access

Sarepta Therapeutics Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=SRPT&period=max&api_key=YOUR_API_KEY